News | December 31, 2024
Senores Pharmaceuticals IPO lists at 53% premium
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
